Identification and Validation of Immune-Related Methylation Clusters for Predicting Immune Activity and Prognosis in Breast Cancer
- 1Department of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
- 2Department of Infectious Diseases and Endemic Disease Control, Haizhu District Center for Disease Control and Prevention, Guangzhou, China
- 3Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
- 4Department of Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- 6Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
- 7Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
A Corrigendum on:
Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer
By Yang A, Zhou Y, Kong Y, Wei X, Ye F, Zhang L, Zhong X, Li M, Lu S, An X and Xiao W (2021) Front. Immunol. 12:704557. doi: 10.3389/fimmu.2021.704557
In the published article, there was an error regarding the affiliations for Weikai Xiao. The affiliation of Weikai Xiao should only be 7, but not 1.
In the published article, there was also an error in the Funding statement. This previously stated: The approval number of the National Natural Science Foundation of China was displayed as “8203066”. And the approval number of Guangzhou basic and applied basic research project (approved in 2021).
The correct Funding statement appears below.
FUNDING
This research is funded by the National Natural Science Foundation of China (approval No.: 82003066), Guangzhou basic and applied basic research project (202102020168), and special science and Technology Fund (Doctoral entrepreneurship project) of Guangdong People’s Hospital and Guangdong Provincial Medical Research Fund (a2021080).
The authors apologize for these error and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: DNA methylation, IRMGs, immune infiltration, prognosis, breast cancer
Citation: Yang A, Zhou Y, Kong Y, Wei X, Ye F, Zhang L, Zhong X, Li M, Lu S, An X and Xiao W (2024) Corrigendum: Identification and validation of immune-related methylation clusters for predicting immune activity and prognosis in breast cancer. Front. Immunol. 15:1372991. doi: 10.3389/fimmu.2024.1372991
Received: 19 January 2024; Accepted: 22 January 2024;
Published: 31 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Yang, Zhou, Kong, Wei, Ye, Zhang, Zhong, Li, Lu, An and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xin An, YW54aW5Ac3lzdWNjLm9yZy5jbg==; Weikai Xiao, eGlhb3drQHN5c3VjYy5vcmcuY24=
†These authors have contributed equally to this work